Q4 FY26 revenue rose 40% year-over-year to $2.3 million, with strong growth in HIV and OEM segments. Cash on hand was $3.7 million, and the company remains debt free. New product development and international expansion are expected to drive further growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.